Neurosarcoidosis



Patompong Ungprasert, MD^{a,b,*}, Eric L. Matteson, MD, MPH^{a,C}

KEYWORDS

- Sarcoidosis Neurosarcoidosis Clinical manifestation Imaging study
- Treatment Outcome

KEY POINTS

- Neurosarcoidosis occurs in 3% to 10% of patients with sarcoidosis.
- Any part of the nervous system can be affected with cranial neuropathy and meningeal involvement being the most common manifestations.
- Glucocorticoids are the main therapy, although immunosuppressive agents are also often required because of the high rate of relapse.

INTRODUCTION

Sarcoidosis is a chronic granulomatous disease of unknown cause characterized by the presence of noncaseating granuloma. ^{1,2} Incidence of sarcoidosis differs considerably among ethnic groups and sexes, ranging from less than 1 new case per 100,000 per year among Japanese men to more than 70 new cases per 100,000 among African American women. ^{3–5} Sarcoidosis can virtually affect any organ including the nervous system with the reported prevalence of neurologic involvement between 3% and 10% of patients. ^{3,5–8} However, the true prevalence of neurosarcoidosis could be much higher as post-mortem studies report that only half of patients with neurosarcoidosis were recognized antemortem. ^{9,10}

CLINICAL FEATURES

Any part of the nervous system can be affected by sarcoidosis, and multiple lesions are often noted. 11–13 The frequency of each neurologic manifestation is summarized in **Table 1**. Neurologic abnormalities are one of the first clinical manifestations that

Disclosure Statement: The authors have no financial or nonfinancial potential conflicts of interest to declare.

E-mail addresses: P.Ungprasert@gmail.com; Ungprasert.Patompong@mayo.edu

Rheum Dis Clin N Am 43 (2017) 593–606 http://dx.doi.org/10.1016/j.rdc.2017.06.008

^a Division of Rheumatology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science, 200 First Avenue Southwest, Rochester, MN 55905, USA; ^b Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Prannok Road, Bangkok 10700, Thailand; ^c Division of Epidemiology, Department of Health Science Research, Mayo Clinic College of Medicine and Science, 200 First Avenue Southwest, Rochester, MN 55905, USA

^{*} Corresponding author. Division of Rheumatology, Mayo Clinic, 200 First Avenue Southwest, Rochester, MN 55905.

Table 1 Frequency of each neurologic manifestation among patients with neurosarcoidosis	
Neurologic Manifestation	Frequency, %
Facial nerve neuropathy	11–25
Optic neuritis	7–35
Vestibulocochlear nerve involvement	3–17
Meningitis	10–20
Intraparenchymal brain lesions on imaging studies	Up to 50
Seizure	15
Depression	60
Neuroendocrinologic dysfunction	2–8
Spinal cord involvement	5–20
Peripheral neuropathy	2–86

lead to the diagnosis of sarcoidosis in 70% to 80% of patients with neurosarcoidosis. ^{13–15} Isolated neurosarcoidosis is uncommon, because more than 90% of patients also have sarcoidosis in other organs, especially the lungs and mediastinal lymph nodes. ^{5,11–13} One study found that more than 80% of patients with an initial diagnosis of isolated neurosarcoidosis eventually developed extraneurologic sarcoidosis over the course of more than 6.6 years of follow-up. ¹⁴

Cranial Neuropathy

Cranial neuropathy is the most common manifestation of neurosarcoidosis. Involvement of all cranial nerves has been reported, with cranial nerve II, VII, and VIII being the most frequently affected. An older cohort suggested that facial nerve palsy accounted for two-thirds of neurosarcoidosis. More recent studies report that facial nerve palsy occurs in 11% to 25% of cases. About one-third of facial nerve palsies are bilateral and could be either concurrent or sequential. 2,15,16

It was formerly thought that facial nerve palsy is a consequence of sarcoidosis-associated inflammation of the parotid gland as classically described as Heerfordt syndrome. However, more recent studies have failed to demonstrate a relationship between the 2 conditions. One study reported that only 20% of patients with facial nerve palsy had associated parotitis, whereas another study reported no facial nerve palsy in 7 patients with parotitis due to sarcoidosis. Epineural inflammation, perineural inflammation, and external compression by granulomatous mass/inflammation in leptomeninges are now more commonly accepted as the cause of cranial neuropathies, including facial nerve palsy. The prognosis of cranial nerve involvement is generally good with complete recovery in more than 85% of cases. 13,15,20

Optic neuritis accounts for 7% to 35% neurosarcoidosis cases. ^{13–17} Bilateral involvement is slightly more common than unilateral disease. ^{14,16,17} Typical presentations include subacute visual loss, retrobulbar pain, and papilledema on examination. ¹¹ Outcome of optic neuritis is quite unfavorable. In one series with average duration of follow-up of 5 years, 30% of patients had visual acuity of 20/200 or worse at last follow-up. ¹⁷ Another series revealed a significant improvement of visual acuity in only 5 out of 18 patients during 18 months of follow-up. ²¹

Involvement of vestibulocochlear nerve resulting in intermittent or persistent sensorineural hearing loss and vestibular dysfunction is seen in 3% to 17% of patients with neurosarcoidosis. ^{14,16,20,21} It is thought to be a consequence of granulomatous meningitis. ²²

Download English Version:

https://daneshyari.com/en/article/5670284

Download Persian Version:

https://daneshyari.com/article/5670284

<u>Daneshyari.com</u>